David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.
Latest from David Wild
Nonprofits are finding new ways to address market gaps and develop treatments for rare diseases with little commercial attraction.
Gingko Bioworks has released a large language model designed to improve mRNA stability.
Beyond the cost savings of biosimilars, the true evolution in wet AMD treatment is happening by companies developing next-generation therapies that aim to reduce injection burden, introduce novel mechanisms, and potentially alter disease progression.
The Centre for Commercialization of Regenerative Medicine has spent over a decade crafting a cell and gene therapy ecosystem in Canada. Now it is replicating the model abroad.
This is Part 1 of a 2-part profile of Hans Clevers, Head of Pharma Research and Early Development at Roche.
Artiva Biotherapeutics is hoping its NK cell therapy approach, which uses un-engineered cells, will prove effective in both oncologic and autoimmune indications and safe enough to be given in the community setting.